Our Latest News
Allergan Partners with TARGET PharmaSolutions…
When pharmaceutical companies win regulatory approval for a drug to be sold – a long and expensive journey that requires successful phase 1, 2 and 3 clinical trials – their work is far from over.
They are increasingly required by the Food and Drug Administration to monitor how safe and…
TARGET PharmaSolutions Partners with Bristol-Myers Squibb, Offering a New Platform to Collect Real World Data
CHAPEL HILL, NC – (November 10, 2016) – TARGET PharmaSolutions, Inc., a clinical data company focused on real world evidence, is pleased to announce two new collaborations with Bristol-Myers Squibb (BMY) to advance the understanding of treatment patterns in nonalcoholic steatohepatitis (NASH)…
Intercept Announces OCALIVA® (OBETICHOLIC ACID) Data in PBC to be Presented at the 2016 AASLD Annual Meeting
Source: Intercept Pharmaceuticals, Inc. November 01, 2016 07:05 ET
Intercept Announces Ocaliva® (Obeticholic Acid) Data in PBC to be Presented at the 2016 AASLD Annual Meeting. Intercept will collaborate with academic leaders on a new NASH patient registry.
NEW YORK, Nov. 01,…
TARGET PharmaSolutions Launches Two Disease State Communities to Better Understand Real World Outcomes
CHAPEL HILL, NC – (September 30, 2016) – TARGET PharmaSolutions, Inc., a clinical data company focused on real world evidence, is pleased to announce the launch of two disease state communities: TARGET-HCC (Hepatocellular Carcinoma) and TARGET-NASH (Nonalcoholic Steatohepatitis). The TARGET…
RESEARCH TRIANGLE PARK, N.C. – The North Carolina Biotechnology Center awarded 36 loans and grants totaling nearly $2.5 million to universities and bioscience companies during the fourth quarter of its 2015-2016 fiscal year ending June 30.
The awards support life science research,…